Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Clinical Perspective on Recent Dermatology Advances: Surveillance, Therapies, Risks, AI, and Practice Updates
Description
This talk reviewed recent dermatology literature from a clinician’s perspective, focusing on what is most likely to change practice. It highlighted active surveillance for selected keratinocyte carcinomas in older or frail patients as a shared decision-making option when lesions are low risk, while emphasizing definitive treatment for high-risk tumors. For interdigital tinea pedis, it noted that many antifungal prescriptions may be unnecessary and that simple adjuncts like cotton finger socks can improve outcomes. In hidradenitis suppurativa, the speaker reviewed its heavy disease burden, comorbidities, evolving biologic and JAK inhibitor data, and rare but important safety signals. The presentation also discussed early hydroxychloroquine for cutaneous lupus as a strategy that may reduce progression to systemic lupus, while updating monitoring practices, including eye and cardiac screening, and noting QT and cardiomyopathy concerns. It covered JAK inhibitors broadly, including boxed warnings and the newly recognized issue of weight gain. Other topics included sexual dysfunction as an underrecognized problem in inflammatory skin disease, calciphylaxis risk factors and poor prognosis despite improved multidisciplinary care, tranexamic acid for melasma with attention to thrombosis risk and possible anti-melanoma effects, isotretinoin and dupilumab in relation to growth and epiphyseal closure, multidrug-resistant Candida auris and experimental photodynamic therapy, and a small study suggesting saline soaks may help recalcitrant plantar warts. The talk closed with a discussion of artificial intelligence in dermatology, stressing trust, clinical oversight, and the need for critical appraisal, lifelong learning, and thoughtful use of new tools to augment rather than replace physician judgment.
View moreConclusions
- Active surveillance can be a reasonable option for select low-risk keratinocyte carcinomas in older or frail patients, but high-risk clinical or histologic features still warrant definitive treatment.
- Simple adjunctive measures, such as cotton toe socks and foot-drying strategies, can meaningfully improve outcomes in interdigital tinea pedis and may reduce unnecessary antifungal prescribing.
- Hidradenitis suppurativa remains a highly morbid, multisystem disease, but expanding medical and surgical options are steadily improving the outlook for affected patients.
- Early hydroxychloroquine in cutaneous lupus may reduce progression to systemic lupus in high-risk patients, making earlier treatment a potentially important game changer.
- Hydroxychloroquine remains a versatile dermatologic workhorse, but clinicians should pay closer attention to ocular, ECG, renal, and tuberculosis-related monitoring issues.
- JAK inhibitors are becoming central to dermatology, yet they require ongoing counseling and monitoring because boxed-warning risks, including infection, thrombosis, malignancy, and weight gain, remain clinically relevant.
- Sexual dysfunction is an underrecognized but important issue in dermatology, and clinicians should ask about it directly rather than assume patients will volunteer the problem.
- Calciphylaxis prognosis has improved with earlier recognition and multidisciplinary care, but mortality is still unacceptably high and better preventive strategies are needed.
- Tranexamic acid may have broader dermatologic applications than melasma, but its thrombotic risk means it should be used cautiously and only with careful patient selection.
- Available data are reassuring that pediatric isotretinoin does not appear to reduce final adult height, and dupilumab may be less concerning for growth than conventional systemic therapy in children with atopic dermatitis.
- Multidrug-resistant Candida auris underscores the need for new antifungal and non-antibiotic approaches, with antimicrobial photodynamic therapy showing promise in preclinical models.
- Saturated saline soaks may be a surprisingly effective, low-cost option for recalcitrant plantar warts, although stronger randomized evidence is still needed.
- Artificial intelligence is likely to become an important dermatology aid, but its usefulness depends on trust, clinical oversight, skeptical interpretation, and verification against primary literature.
- The central skill for modern dermatologists is not just access to information but critical appraisal, because medical knowledge is expanding too quickly for passive consumption alone.
- Career-long learning in dermatology now requires a blend of broad scanning, deeper dives, and the willingness to keep updating practice as evidence changes.
- Jeon HS, Choi M, Byun SJ, Suh LH. Atopic dermatitis is not a risk factor for keratoconus: a population-based cohort study. J Am Acad Dermatol. 2018;79:160-162.#10.1016/j.jaad.2018.02.039
- Boudreaux B, Christensen H, Porter HJ, Eaton J, Ludlow J, Holmes T, Bui MR. Oncologic outcomes for invasive squamous cell carcinoma with a clinically resolved biopsy site managed by watchful waiting: A retrospective cohort study. J Am Acad Dermatol. 2025 Apr;92(4):801-806.#10.1016/j.jaad.2024.11.067
- Gold JAW, et al. High rates of potentially unnecessary topical antifungal prescribing in a large commercial health insurance claims database, United States. J Am Acad Dermatol. 2025 May;92(5):1119-1121.#10.1016/j.jaad.2025.01.022
- Aksoy H, et al. Journal of the American Academy of Dermatology, 2025. Study of finger socks with topical antifungal therapy for interdigital tinea pedis.
- Wiala A, et al. Patients with Psoriasis and Suppurative Hidradenitis (PSO-SH) share genetic risk factors and are at risk of increased morbidity. J Am Acad Dermatol. 2025 Jun;92(6):1303-1311.#10.1016/j.jaad.2025.02.015
- Bar D, Baum S, Segal Z, Barzilai A, Druyan A, Lidar M. Early initiation of hydroxychloroquine in cutaneous lupus erythematosus to prevent progression to systemic lupus erythematosus: A long-term follow-up study. J Am Acad Dermatol. 2025 Jul;93(1):55-63.#10.1016/j.jaad.2025.02.066
- Gaffney, R.G. and Werth, V.P. Evaluating results of an interferon-g release assay in patients with autoimmune disease who are taking hydroxychloroquine. J Am Acad Dermatol. 2019;80:1162-1164.#10.1016/j.jaad.2018.12.027
- Ezeh N, Ardalan K, Buhr KA, Nguyen C, et al. Cross-sectional characteristics of pediatric-onset discoid lupus erythematosus: Results of a multicenter, retrospective cohort study. J Am Acad Dermatol. 2022 Sep;87(3):559-566.#10.1016/j.jaad.2022.04.028
- Joshi A, Gawey L, Rahman M, Ghanshani R, Tran KA, Hsiao JL, Shi VY. Postmarketing safety analysis of upadacitinib in atopic dermatitis: A Food and Drug Administration adverse reporting system review of boxed warning-related adverse events. J Am Acad Dermatol. 2025 Aug;93(2):479-481.#10.1016/j.jaad.2025.04.046
- Cheeley JT, Jagannathan G, Ellis CL, O’Neill WC. Histologic comparison of normal and diseased skin in patients with suspected calciphylaxis. J Am Acad Dermatol. 2025 Oct;93(4):975-979.#10.1016/j.jaad.2025.05.1404
- Glennon CM, Xia J, Strowd L, Dominguez AR, Haynes D, Keller J, Locascio JJ, Micheletti RG, Ortega Loayza AG, Pasieka HB, Shinohara MM, Tan AJ, Nigwekar SU, Kroshinsky D. Outcomes and mortality in calciphylaxis: A multicenter update. J Am Acad Dermatol. 2025 Oct;93(4):966-974.#10.1016/j.jaad.2025.04.081
- Schmidt M, Vu M, Gandhi S, Wilkerson M. A retrospective cohort study evaluating the impact of tranexamic acid on melanoma risk. J Am Acad Dermatol. 2025 Nov;93(5):1301-1303.#10.1016/j.jaad.2025.07.006
- Xu Y, Li T, Liang X, Jia S, Wang L, Zhu Z, Yu L, Zhang T. Saturated saline immersion for the treatment of refractory plantar warts: An open-label, one-arm, single-center trial. J Am Acad Dermatol. 2026 Feb;94(2):525-529.#10.1016/j.jaad.2025.10.014
- Liu X, Guo S, Wang J, Zhang L, Lin Y, Liu Y, Ouyang J, Shi D, Xu B, Fang W, Ran Y. Caged-hypocrellin-mediated antimicrobial photodynamic therapy as a dual-action strategy for fungal clearance and immune response regulation in drug-resistant Candida auris wound infections. J Am Acad Dermatol. 2026 Jan;94(1):73-80.#10.1016/j.jaad.2025.08.040